Clinical collaboration puts fresh focus on Incyte stock

Incyte (INCY) is back on investor radars after Adagene announced a clinical collaboration, pairing muzastotug with Incyte’s bispecific antibody INCA33890 in microsatellite stable colorectal cancer.

The planned Phase 1 study, expected to start in 2026, will be sponsored and conducted by Incyte. It will initially assess safety and tolerability before moving into an efficacy expansion cohort.

The collaboration headlines come as Incyte’s share price, now at US$97.69, shows short term momentum with a 1 month share price return of 5.57% but a 90 day share price return decline of 7.8%, while the 1 year total shareholder return of 67.11% points to stronger longer term gains.

If you are looking beyond Incyte for other cancer and biotech stories tapping into next generation treatments, it could be worth scanning 34 healthcare AI stocks

With Incyte trading at US$97.69 and a consensus price target of US$107.27, along with mixed recent returns but a 67.11% 1 year total shareholder return, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 2% Undervalued

Incyte’s most followed narrative pegs fair value at about $100.10, just above the current $97.69 share price. This frames the move as a fine valuation gap rather than a deep discount.

The upcoming launches and label expansions of therapies like Opzelura, povorcitinib, and Niktimvo in high value indications such as atopic dermatitis, vitiligo, hidradenitis suppurativa, and GVHD, along with a late stage pipeline of targeted drugs, position Incyte to benefit from heightened demand for advanced immunology and oncology treatments as global populations age, likely supporting sustained revenue growth and future earnings. Recent advances in precision medicine, exemplified by early clinical data for mutant CALR antibody 989 and mutation specific diagnostics partnerships, directly align with accelerating industry adoption of targeted therapies, expanding total addressable markets and improving the probability of commercial success.

Curious what assumptions sit behind that modest upside call? Revenue trends, margins, and future earnings multiples all play a crucial role in this fair value story. The narrative connects them in a way the headline price alone cannot.

Result: Fair Value of $100.10 (UNDERVALUED)

However, high reliance on Jakafi and the risk of pipeline setbacks or delays could quickly challenge the modest undervaluation story that investors are leaning on.

Another Angle on Valuation

While the most popular narrative points to a fair value of $100.10 and a slight 2.4% undervaluation, our DCF model paints a different picture. On that view, Incyte at $97.69 sits well above an estimated future cash flow value of $50.26, which implies the shares look expensive. Which lens do you think better fits a business facing forecast declines in revenue and earnings over the next few years?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Incyte for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 57 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With a mix of enthusiasm around new trials and concern about concentration and pipeline risk, the picture is clearly mixed. Take a moment to review the numbers and narratives yourself, then weigh up the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one company, you risk missing opportunities that might fit your goals even better. Take a moment to scan a few focused stock ideas:

• Zero in on potential mispricings by checking companies that appear attractively valued on both quality and price using the 57 high quality undervalued stocks.
• Strengthen your income focus by reviewing businesses that combine higher yields with an emphasis on resilience via the 12 dividend fortresses.
• Protect the downside first by shortlisting companies with sturdier financial profiles through the solid balance sheet and fundamentals stocks screener (41 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.